Related Experiment Video
Updated: May 23, 2026
05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
Insulin degludec--a new-generation basal insulin
1Hull Royal Infirmary, Michael White Diabetes Centre, 220-236 Anlaby Raod, Hull HU3 2RW, UK. ammar.wakil@gmail.com
Expert Opinion on Biological Therapy
|March 27, 2012
Summary
Insulin degludec offers flexible dosing for patients needing lifestyle adaptability. This basal insulin may also lower hypoglycemia risk compared to existing options.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Diabetes management requires consistent insulin therapy.
- Patient lifestyle factors can impact adherence to insulin regimens.
- Current basal insulins may present challenges in flexibility and hypoglycemia risk.
Purpose of the Study:
- To evaluate insulin degludec as a flexible dosing option.
- To compare the safety and efficacy of insulin degludec against currently available basal insulins.
- To assess the potential for reduced hypoglycemia risk with insulin degludec.
Main Methods:
- Clinical trials comparing insulin degludec to other basal insulins.
- Assessment of patient-reported outcomes regarding dosing flexibility.
- Monitoring of hypoglycemia events and glycemic control.
Main Results:
- Insulin degludec demonstrated potential for flexible dosing schedules.
- A reduced risk of hypoglycemia was observed with insulin degludec compared to other basal insulins.
- Effective glycemic control was maintained with insulin degludec.
Conclusions:
- Insulin degludec provides a valuable alternative for patients needing dosing flexibility.
- The use of insulin degludec may contribute to improved patient adherence and safety by reducing hypoglycemia.
- Insulin degludec represents an advancement in basal insulin therapy for type 1 and type 2 diabetes management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...